Summary of a workshop on nonclinical and clinical immunotoxicity assessment of immunomodulatory drugs Immunotoxicity assessment of immunomodulators J. R. Piccotti et al.

Journal of Immunotoxicology

Volumn 6, Issue 1, 2009, Pages 1-10

  Piccotti, Joseph R ^a   Lebrec, Herve N ^b   Evans, Ellen ^a   Herzyk, Danuta J ^a   Hastings, Kenneth L ^c   Burns Naas, Leigh Ann ^d   Gourley, Ian S ^d   Wierda, Daniel ^e   Kawabata, Thomas T ^d  

^a MERCK RESEARCH LABORATORIES   (United States)

^b AMGEN INC   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d PFIZER INC   (United States)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

Anti inflammatory; Immunomodulators; Immunotoxicity; ITC; Workshop

Indexed keywords

ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANTIBODY RESPONSE; BIOASSAY; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSTIMULATION; IMMUNOTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; RISK ASSESSMENT; T LYMPHOCYTE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CLINICAL TRIALS AS TOPIC; CONSENSUS; DATA COLLECTION; DRUG APPROVAL; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; HUMANS; IMMUNE SYSTEM; IMMUNOLOGIC FACTORS; MODELS, ANIMAL; RISK ASSESSMENT; TOXICITY TESTS;

EID: 70350434103     PISSN: 1547691X     EISSN: 1547691X     Source Type: Journal    
DOI: 10.1080/15476910802656440     Document Type: Review

References (14)

1. Bonilla, F. A. and Geha, R. S. 2006. Update on primary immunodeficiency diseases. J. Allergy Clin. Immunol. 117:S435-441.
2. Burleson, G. R. and Burleson, F. G. 2008. Testing human biologicals in animal host resistance models. J. Immunotoxicol. 5:23-31.
3. Chapman, K., Pullen, N., Graham, M., and Ragan, I. 2007. Nonclinical safety testing of monoclonal antibodies: the significance of species relevance. Nature Rev./Drug Discov. 6:120-126.
4. CHMP (Committee for Medicinal Products for Human Use). 2007. Guideline on strategies to identify and mitigate risks for first-in-man clinical trials with investigational medicinal products. EMEA/ CHMP/SWP/28367.
5. ESG (Expert Scientific Group) on Phase One Clinical Trials: Final report (Norwich, US: Stationery Office, 2006. http://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsPolicyAnd Guidance/DH-063117.
6. HESI Immunotoxicology Technical Committee, Clinical Immunotoxicology Workshop, Meeting Minutes, February, 2005. http://www.hesiglobal.org/NR/ rdonlyres/18E51EC7-BFEC-4799-AA30-87FBE57D8D23/0/AttachmentG.doc.
7. ICH (International Conference on Harmonization). 2000. Guidance for Industry. M3 Nonclinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals.
8. ICH (International Conference on Harmonization). 2006. Guidance for Industry. S8 Immunotoxicity Studies for Human Pharmaceuticals.
9. Mohan, V. P., Scanga, C. A., Keming, Y., Scott, H. M., Tanaka, K. E., Tsang, E., Tsai, M. C., Flynn, J. L., and Chan, J. 2001. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: Possible role of limiting pathology. Infect. Immun. 69:1847-1855.
10. O'Brien, D. P., Briles, D. E., Szalai, A. J., Tu, A. H., Sanz, I., and Nahm, M. H. 1999. Tumor necrosis factor-d receptor I is important for survival from Streptococcus pneumoniae infections. Infect. Immun. 67:595-601.
11. Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., and Panoskaltsis, N. 2006. Cytokine storm in a Phase 1 trial of anti-CD28 monoclonal antibody TGN1412. New Engl. J. Med. 355:1018-1028.
12. Treacy, G. 2000. Using an analogous monoclonal antibody to evaluate the reproductive and chronic toxicity potential for a humanized anti- TNFd monoclonal antibody. Hum. Exp. Toxicol. 19: 226-228.
13. Weaver, J. L., Tsutsui, N., Hisada, S., Vidal, J.-M., Spanhaak, S., Sawada, J., Hastings, K. L., van der Laan J.W., van Loveren H., Kawabata, T.T., Sims, J., Durham, S. K., Fueki, O., Matula, T. I., Kusunoki, H., Ulrich, P., and Nakamura, K. 2005. Development of the ICH guidelines for immunotoxicology evaluation of pharmaceuticals using a survey of industry practices. J. Immunotoxicol. 2:171-180.
14. Yousry, T. A., Major, E. O., Ryschkewitsch, C., Fahle, G., Fischer, S., Hou, J., Curfman, B., Miszkiel, K., Mueller-Lenke, N., Sanchez, E., Barkhof, F., Radue, E. W., Jäger, H. R., and Clifford, D. B. 2006. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. New Engl. J. Med. 354:924-933.